Nurosene Appoints Netrmark Co-Founder Dr. Joseph Geraci PhD as Chief Scientific Officer
Nurosene Health Inc., a healthtech company focused on building a generation of better brains, announced that it has appointed Dr. Joseph Geraci, PhD as the company’s Chief Scientific Officer. In this newly created leadership role at Nurosene, Dr. Geraci will bring his extensive knowledge base to assist in the integration of NetraMark’s proprietary AI technology to advance the development of Nurosene’s platform to formulate precision solutions for mental health and wellness.
Further to the Company’s press release dated October 12, 2021, the Company has completed its acquisition of NetraMark Corp. NetraMark utilizes AI and machine learning to optimize the path to new drug development, accelerate clinical trials and redefine the landscape of how disorders are treated. Accordingly, NetraMark is now a wholly-owned subsidiary of Nurosene.
Recommended AI News: Tech Startup, Bank of Kicks, Plans to Launch First Crypto Bank Backed by Sneakers
“We are thrilled to officially welcome Dr. Geraci to the Nurosene executive leadership team as we move toward ambitiously designing the future of healthcare using data and precision insights,” said Ranj Bath, CEO of Nurosene. “Dr. Geraci possesses an incredible wealth of both technical and medical experience that will help the company create new precision solutions that will empower end-users to own their brain health and overall healthcare path forward.”
Dr. Geraci is a mathematician, computer scientist, and medical scientist with over 12 years of experience with mathematical medicine and artificial intelligence for medical applications. His academic work spans quantum computation, oncology, neuropsychiatry, and AI. His work in quantum computation was originally focused on how this next generation of computation could impact problems that classical computers have trouble with. He holds post doctorates in machine learning, oncology and neuropsychiatry.
Recommended AI News: Alibaba Cloud Unveils New Server Chips to Optimize Cloud Computing Services
Dr. Geraci is also the co-founder of NetraMark, a pharmatech company that utilizes AI and novel mathematical methods and quantum computing to optimize the path to new drug development, accelerate clinical trials, and redefine the landscape of how disorders are treated. Specifically, he created a novel paradigm of machine intelligence that is capable of providing extraordinary insights into complex data sets, like those found in clinical trials. This technology, known as NetraAI, was created to help medical scientists not only understand the underlying causes of disease, but to also redefine the way we think about and classify disease.
“I am excited to be a key part of Nurosene’s journey and working towards improving the future of healthcare and mental health using the power of technology,” said Dr. Geraci. “AI holds a lot of promise, but there are critical issues with using it for complex data sets like you find within patient populations, or data that you get from apps. My work over the last 5 years has been focused on using a new kind of machine intelligence that helps all the great machine learning algorithms to learn more effectively from complex disease data sets. It’s like having a big brother for your AI. These next generation data science capabilities, coupled with Nurosene’s platform, will allow us to gather the most complete perspective on human health, and these insights can drive innovation in various disease states, especially mental health.”
[To share your insights with us, please write to email@example.com]